On October 14, 2026 Caris Life Sciences (NASDAQ: CAI), a leading TechBio company, reported that researchers from Caris and the Caris Precision Oncology Alliance (Caris POA) will present eight posters at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The research showcases the expanding impact of artificial intelligence, molecular profiling and multimodal data integration in advancing precision oncology across multiple tumor types.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The two Caris-led posters focus on AI-driven treatment prediction and risk stratification in breast cancer, as well as six collaborative investigations conducted with members of the Caris POA. Together, the posters span breast, lung, endometrial, melanoma and immuno-oncology research and demonstrate how comprehensive molecular and clinico-genomic data can reveal novel biological insights and inform more personalized treatment approaches.

"Artificial intelligence is transforming our ability to understand cancer biology and predict therapeutic response on an unprecedented scale," said James Hamrick MD, MPH, Chairman of the Caris POA. "The posters to be presented at ESMO (Free ESMO Whitepaper) 2026 highlight how the integration of AI, molecular profiling and real-world clinical data can uncover clinically meaningful insights that ultimately help guide more precise treatment decisions for patients."

Caris-Led Studies

Posters:
178P – Caris CapeAI, An Artificial Intelligence Model of ER+ Breast Cancer Response to Capecitabine
Authors: Javier Pascual Lopez, Chen Sun, Miguel J. Gil, et al.
Session: AI for clinical workflows and decision-making
Date and time: Sunday, 25 October 2026, 12:00–12:45 (Madrid time)

217P – Toward Precision Extended Endocrine Therapy in Early HR+ Breast Cancer: Multimodal AI for Risk and Benefit Stratification
Authors: Eleftherios P. Mamounas, Md Ashequr Rahman, Ming Chen, et al.
Session: AI for clinical workflows and decision-making
Date and time: Sunday, 25 October 2026, 12:00–12:45 (Madrid time)

Caris Precision Oncology Alliance Collaborative Studies

Posters:
3285P – Characterization of G-protein coupled estrogen receptor (GPER) and estrogen receptor in EGFR-mutated NSCLC leading to survival differences
Authors: Robert Hsu, Mercy Kehinde-Ige, Sharon Wu, et al.
Session: Pathology and molecular pathology
Date and time: Friday, 23 October 2026, 15:15–16:00 (Madrid time)

1296P – Genomic Scar–Defined Homologous Recombination Deficiency (HRD) and Tumor Immune Microenvironment in Endometrial Cancer (EC)
Authors: Hiromichi Nakajima, Kenichi Harano, Sharon Wu, et al.
Session: Gynecological cancers
Date and time: Monday, 26 October 2026, 12:00–12:45 (Madrid time)

4395P – A 25-gene T-cell exhaustion signature refines TLS-based prediction of immunotherapy benefit
Authors: Nathan El Ghazzi, Andrew Elliott, George Sledge, et al.
Session: Translational research and biomarkers
Date and time: Friday, 23 October 2026, 15:15–16:00 (Madrid time)

2136P – Site-dependent stromal-mesenchymal reprogramming associated with survival and immunotherapy outcomes in BAP1-mutant uveal melanoma (UM)
Authors: Clara J. Oh, Jingshu Chen, Nishant Gandhi, et al.
Session: Melanoma
Date and time: Saturday, 24 October 2026, 12:00–12:45 (Madrid time)

2681P – Characterization of differences across Organ Site Specific Metastasis in NSCLC by Race/Ethnicity
Authors: Robert Hsu, Nishant Gandhi, Krithika Chennapan, et al.
Session: NSCLC, metastatic
Date and time: Monday, 26 October 2026, 12:00–12:45 (Madrid time)

2686P – RRAS2mt Non-small cell lung cancer (NSCLC) defines a distinct subset of RASmt NSCLC
Authors: Sharon Wu, Hui Jing Hoe, Eleonora Gariazzo, et al.
Session: NSCLC, metastatic
Date and time: Monday, 26 October 2026, 12:00–12:45 (Madrid time)

Research highlights will be available at the Caris booth #1021.

(Press release, Caris Life Sciences, OCT 14, 2026, View Source [SID1234673462])

On October 14, 2026 Pierre Fabre Pharmaceuticals Inc. (PFP) reported the acceptance by U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) resubmission for tabelecleucel, with a proposed indication as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"People diagnosed with relapsed or refractory EBV+ PTLD urgently need new treatment options as they have no approved FDA therapies, and after failure of initial treatment their survival is limited, measured in only weeks to months," said Adriana Herrera, Chief Executive Officer of PFP, the Laboratoires Pierre Fabre Pharmaceutical subsidiary in the U.S. "We look forward to a collaborative review process focused on the growing body of evidence supporting tabelecleucel approval including more patients and increased follow-up within our pivotal study and extensive supplemental data primarily from our ongoing early access programs and commercial experience in Europe."

PFP resubmitted the BLA based on April 2026 Type A meeting alignment with the FDA. The submission includes an updated dataset with additional patients and longer follow-up from the ongoing, pivotal Phase 3 single-arm ALLELE study of tabelecleucel in adults and children two years of age and older with relapsed/refractory EBV+ PTLD following SOT or HCT. The resubmission also includes additional supplemental data from expanded access programs, a separate clinical study, and commercial experience in Europe.

"When your child receives a transplant, you celebrate. You breathe again. You start to imagine a future, but then sometimes, the phone rings with news that no parent should ever have to hear: your child has cancer," said Melissa McQueen, President of Transplant Families, a pediatric non-profit connecting heart, liver, kidney, and bone marrow transplant patients and families. "We are hopeful that following the extensive dialogue with FDA, this resubmission will result in a path to patient access for U.S. families."

Tabelecleucel is an allogeneic, off-the-shelf, EBV-specific T-cell immunotherapy which is designed to target and attack EBV-infected cells. It was granted marketing authorization under the brand name EBVALLO in December 2022 by the European Commission. Marketing authorization was also granted by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom in May 2023 and by Swissmedic in Switzerland in May 2024. In the U.S., tabelecleucel is investigational and has not yet been approved by the FDA. For eligible patients, it is available through clinical trials and expanded access programs.

About EBV+PTLD
EBV+ PTLD is an ultra-rare, acute, and potentially deadly hematologic malignancy that occurs after transplantation when patient T-cell immune responses are compromised by immunosuppression. It can impact patients who have undergone SOT or allogeneic HCT. SOT patients have a life-long risk of contracting the disease. Poor median survival of 3 weeks and 4.1 months for HCT and SOT, respectively, is reported in EBV+ PTLD patients for whom initial treatment failed, underscoring the significant need for new therapeutic options.

(Press release, Pierre Fabre, OCT 14, 2026, View Source [SID1234673461])

On October 14, 2026 Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), reported that the first patient has been dosed in the clinical study of spevatamig for the treatment of colorectal cancer (CRC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47. It was granted by the FDA orphan drug designation for the treatment of pancreatic cancer in 2022, Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024, and recently, Fast Track designation for the treatment of advanced and metastatic biliary tract carcinoma. In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with pembrolizumab. Spevatamig is an innate immunity enhancer (I2E), an emerging class of IO agents. It has the potential to become the first I2E for a solid tumor indication and is combinable with various anti-cancer therapies.

The multi-center Phase I/II clinical trial of spevatamig (NCT05482893), known as the TWINPEAK study, is currently evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of spevatamig in patients with advanced gastrointestinal cancers, including gastric, gastroesophageal Junction, pancreatic ductal, CRC or biliary tract adenocarcinomas. The Phase I (CTR20241655) and Phase II (CTR20252758) clinical trials of spevatamig in China are currently recruiting patients with gastrointestinal cancers.

(Press release, Phanes Therapeutics, OCT 14, 2026, View Source [SID1234673460])

On October 14, 2026 Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, reported two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

European Society of Gene and Cell Therapy (ESGCT) Congress
Title: Novel targeted LNP delivery achieved in vivo CAR-T cell generation resulting in therapeutically relevant B-cell depletion
Session Date and Time: Wednesday, October 28, 2026, 1:30 – 3:30 p.m. CET
Session Title: Poster Session 1
Presenter: Harry An, Director, Process Development, Editas Medicine
Final Abstract Number: P0361

Title: Development of a configurable, GMP-ready manufacturing platform for targeted LNP therapeutics
Session Date and Time: Wednesday, October 28, 2026, 1:30 – 3:30 p.m. CET
Session Title: Poster Session 1
Presenter: Harry An, Director, Process Development, Editas Medicine
Final Abstract Number: P0781
Abstracts can be accessed on the conference website as they become available, and presentations will also be posted to the "Posters & Presentations" section of the Company’s website during the conferences.

In addition, management will participate in the following upcoming investor conference in November:

Guggenheim 3rd Annual Healthcare Innovation Conference
Format: Fireside Chat
Date and Time: November 10, 2026, 2:30 p.m. ET
Location: Boston, Massachusetts
To access the live webcast of Editas Medicine’s Fireside Chat, please visit the "Investors" section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event.

(Press release, Editas Medicine, OCT 14, 2026, View Source [SID1234673455])

On October 14, 2026 Affibody AB ("Affibody") reported a series of presentations at the 2026 Congress of the European Association of Nuclear Medicine (EANM), taking place October 17-21 in Vienna. The presentations span both clinical and preclinical research and include results from the ongoing Phase 1 study with the Radioligand Therapy (RLT) candidate ABY-271 in HER2-positive metastatic breast cancer, clinical data with the HER2 PET imaging agent tezatabep matraxetan, and preclinical findings with Affibody molecules targeting B7-H3. Together, the presentations highlight the breadth of Affibody’s capabilities across targeted RLTs and precision imaging.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The wealth and diversity of results being presented at EANM, one of the world’s leading congresses in nuclear medicine and theranostics, reflects both the potential of our Affibody technology and the strength of our collaborations," said David Bejker, Chief Executive Officer of Affibody. "We are excited to see our science translate into meaningful advancements with the aim to address significant unmet needs in patients with hard-to-treat cancers."

Presentations
Title: A First-in-Human Phase 1 Trial Safety and Biodistribution of [¹⁷⁷Lu]Lu-ABY-271 in Subjects with HER2-Positive Metastatic Breast Cancer (NCT07081555)
Presenter: Joachim Feldwisch, Affibody
Session: C: Therapy Clinical Study – C1 Oncological Therapy Clinical Study – C16 Other Oncological Treatments
Format: e-Poster
Presentation ID: EP-0981

Title: Whole-body HER2 PET/CT reveals spatial heterogeneity of HER2 expression in advanced gastroesophageal adenocarcinoma.
Presenter: Antonios Tzortzakakis, Karolinska Institutet
Date and Time: October 18, 2026, 08:00 CEST
Session: Clinical Oncology Track: Gastro-Intestinal Malignancy
Format: Oral
Presentation ID: OP-035

Title: Standardization of image quality and activity quantification in a multi-centre PET imaging study (Ex-PET)
Presenter: Jakob Lagerstedt, Karolinska University Hospital
Date and Time: October 20, 2026, 16:45 CEST
Session: Cutting Edge Science Track: Physics Committee: Quantitative PET:
Harmonisation and Robustness
Format: Oral
Presentation ID: OP-734

Title: Preclinical Evaluation of PNABased Affibody-mediated Pretargeting for targeting HER2: A direct comparison between Tb-161 and Lu-177
Presenter: Maryam Oroujeni, Uppsala University
Date and Time: October 18, 2026, 09:45 CEST
Session: M2M Track: TROP Session – Radiopharmaceutical Sciences Committee: 161Tb vs 177Lu, and The Winner Is…
Format: Oral
Presentation ID: OP-084

Title: Modular Molecular Design of B7H3Targeting Affibody Molecules for Radionuclide Therapy: Biodistribution-Driven Selection and Therapy
Presenter: Maryam Oroujeni, Uppsala University
Date and Time: October 20, 2026, 16:45 CEST
Session: Radiopharmaceutical Sciences Committee: Modern Approaches to Drug Development in Nuclear Medicine
Format: Oral e-Poster
Presentation ID: EPS-223

Title: HER2-Ex PET trial: A multicentre, prospective, open-label study using [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predictive value for HER2 antibody-drug conjugates in patients with metastatic breast cancer.
Presenter: Anna Kistner, Karolinska Institutet
Session: B: Imaging Clinical Studies – B1 Oncological Imaging Clinical Study – B13 Breast
Format: e-Poster
Presentation ID: EP-0261

Title: In vitro evaluation of Affibody molecules targeting B7-H3 for radionuclide therapy of neuroblastoma
Presenter: Maryam Oroujeni, Uppsala University
Session: A: Preclinical and Translational Studies – A1 Medical Preclinical – A11 In Vitro Studies
Format: e-Poster
Presentation ID: EP-0003

Title: Optimized Affibody Molecule targeting B7-H3 immune checkpoint: Improved Tumor Targeting Properties in a Syngeneic MC38 Model
Presenter: Enrique Recasens Pérez-Vera, Uppsala University
Session: A: Preclinical and Translational Studies – A1 Medical Preclinical – A18 New Radiopharmaceuticals – Therapy
Format: e-Poster
Presentation ID: EP-0171

Title: Feasibility of affibody-based pretargeted delivery of 225Ac
Presenter: Vladimir Tolmachev, Uppsala University
Session: A: Preclinical and Translational Studies – A1 Medical Preclinical – A18 New Radiopharmaceuticals – Therapy
Format: e-Poster
Presentation ID: EP-0161

Title: Biodistribution and dosimetry for PET imaging of HER2-receptor expression using [18F]-HER2 in metastatic breast cancer
Presenter: Ulrika Estenberg, Karolinska University Hospital
Session: B: Imaging Clinical Studies – B10 Dosimetry in Diagnostic Applications – B101 Dosimetry in Diagnostic Applications
Format: e-Poster
Presentation ID: EP-0617

View the EANM abstracts here: View Source

About ABY-271

ABY-271 is a Radioligand Therapy (RLT) candidate aimed at tumor cells that express HER2, regardless of their location in the body. The project builds on previous clinical research insights from the development of the PET imaging agent tezatabep matraxetan (ABY-025), showing that the candidate substance can bind to HER2 independently of the tumor origin. ABY-271 with the radioisotope lutetium-177 emits therapeutic beta radiation, exerting irreversible damage to the cancer cells.

About tezatabep matraxetan

Tezatabep matraxetan (ABY-025) is a Gallium-68-labeled PET tracer candidate that aims to enable non-invasive visualization of HER2 expression in cancer patients. The high affinity and rapid clearance of tezatabep matraxetan from blood and normal organs allows HER2 assessment within hours.

About HER2

HER2 is a protein that is involved in cell growth. HER2 is overexpressed by some types of cancer cells, including breast, stomach, esophageal, ovarian, bladder, and pancreatic cancers. HER2 may cause cancer cells to grow more quickly and spread to other parts of the body and HER2-positive cancers are therefore considered more aggressive than HER2-negative cancers. However, they are much more likely to respond to treatments that target the HER2 protein. HER2-targeted therapies can remain effective even after multiple lines of treatment.

About B7-H3

B7-H3 (also known as CD276) is a cell surface immunomodulatory glycoprotein overexpressed by many different types of cancers, whereas its expression is low in most normal organs and tissues. This makes it a promising target for cancer therapies. B7-H3 inhibits tumor specific immune responses and promotes tumor cell proliferation and invasion. High B7-H3 expression is generally associated with poor prognosis.

(Press release, Affibody, OCT 14, 2026, View Source [SID1234673454])